Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem® and Mesigyna®) and one oral contraceptive (Ortho-Novum 1/35®) on coagulation and fibrinolysis

Contraception

Volumn 68, Issue 3, 2003, Pages 159-176

  D'Arcangues, Catherine ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cyclofem; Hemostasis; Injectable contraceptive; Mesigyna; Oral contraceptive

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; FIBRINOGEN; HEMOGLOBIN; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; OTHO NOVUM 1 35; PLASMINOGEN; PROTEIN C; CONTRACEPTIVE AGENT; DRUG DERIVATIVE; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NORETHISTERONE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN;

ADULT; ARTERY DISEASE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; HYPERCOAGULABILITY; MULTICENTER STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; PROTEIN SYNTHESIS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOPLASTIN TIME; VEIN DISEASE; ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INJECTION; PARTIAL THROMBOPLASTIN TIME;

ADOLESCENT; ADULT; ANTITHROMBINS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; DRUG COMBINATIONS; ESTRADIOL; FACTOR VII; FACTOR X; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HEMOGLOBINS; HUMANS; INJECTIONS; MEDROXYPROGESTERONE 17-ACETATE; MESTRANOL; NORETHINDRONE; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN; PLASMINOGEN INACTIVATORS; PLATELET COUNT; PROTEIN C; PROTHROMBIN;

EID: 1642264856     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(03)00164-1     Document Type: Article

References (39)

1. d'Arcangues C., Snow R.C. Injectable contraceptives. Rabe T., Runnebaum B. Fertility control. Update and trends. 1999;121-149 Springer-Verlag, Berlin.
2. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO scientific group. Geneva: World Health Organization, 1998. WHO Technical Reports Series, No. 877. 89 pp.
3. Writing Committee for the Second European Conference on Sex Steroids and Metabolism. Consensus development meeting 1995 combined oral contraceptives and cardiovascular disease. Gynecol Endocrinol. 10:1996;1-5.
4. Robinson G.E. Low-dose combined oral contraceptives. Br J Obstet Gynaecol. 101:1994;1036-1042.
5. Fotherby K., Caldwell A.D.S. New progestogens in oral contraception. Contraception. 49:1994;1-32.
6. Kluft C., Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost. 78:1997;315-326.
7. Winkler U.H. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel- containing oral contraceptives a review. Am J Obstet Gynecol. 179:1998;S51-61.
8. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C a randomised cross-over study. Lancet. 354:(9195):1999;2036-2040.
9. Middeldorp S., Meijers J.C., van den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives a cross-over study. Thromb Haemost. 84:2000;4-8.
10. Meijers J.C., Middeldorp S., Tekelenburg W., et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis a randomised cross-over study of two low-dose oral contraceptives. Thromb Haemost. 84:2000;9-14.
11. Tans G., Curvers J., Middeldorp S., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 84:2000;15-21.
12. Task Force on Oral Contraceptives. WHO Special Programme of Research, Development and Research Training in Human Reproduction. A multicentre study of coagulation and haemostatic variables during oral contraception variations with four formulations. Br J Obstet Gynaecol. 98:1991;1117
13. Dacie JV, Lewis SM. Practical hematology. 6th ed. Edinburgh: Churchill Livingstone, 1984. p. 27-30, 43-5.
14. Ingram G.I.C., Hills M. Reference method for the one-stage prothrombin time test on human blood. Thromb Haemost. 36:1976;237-238.
15. Poller L, Thomson JM. Blood coagulation and haemostasis; a practical guide. 3rd ed. Edinburgh: Churchill Livingstone, 1985. p. 334-6.
16. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bastimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
17. Poller L., Thomson J.M., Sear C.H.J., Thomas W. Identification of a congenital defect of factor VII in a colony of beagle dogs the clinical use of the plasma. J Clin Pathol. 24:1971;626-632.
18. Aurell L., Friberger P., Karlsson G., Claeson G. A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb Res. 11:1977;595-609.
19. Soria J., Soria C., Samama M.M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and studies on thrombolysis. Davidson J.F., Rowan R.M., Samama M.M., Desnoyers P.C. Progress in chemical fibrinolysis and thrombolysis. Vol. 3:1978;337-346 Raven Press, New York.
20. Wiman B., Chmielewska J., Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem. 259:1984;3644-3647.
21. Abildgaard U., Lie M., Odegard O.R. Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH). Thromb Res. 11:1977;549-553.
22. Mancini G., Carbonara A.O., Heremans J.F. Immunological quantitation of antigens by a single radial immunodiffusion. Immunochemistry. 2:1965;235-254.
23. Odegaard O.R., Try K., Abildgaard U. Protein C. A simplified semi-automated activity assay. Thomb Res. 42:1986;257-262.
24. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
25. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 346:1995;1589-1593.
26. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Büller H.R., Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 346:1995;1593-1596.
27. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 344:2001;1527-1535.
28. Kjaeldgaard A., Ahlesteen I., Larsson B., Astedt B. Progestogen regulation of tissue plasminogen activator in a human melanoma cell line. Thromb Res. 49:1988;287-297.
29. Meng Y.-X., Jiang H.-Y., Lu F.-Y. The effects of long-term using once-a-month injectable contraceptive norethisterone enanthate/estradiol valerate on coagulation in the Chinese. Thromb Haemost. 64:1990;548-549.
30. Meng Y.-X., Jiang H.-Y., Chen A.-J., et al. Hemostatic changes in women using a monthly injectable contraceptive for one year. Contraception. 42:1990;455-465.
31. Tiras M.B., Noyan V., Fener N., Guner H., Yildrim M., Darney P.D. Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters. Contraception. 63:2000;151-153.
32. Garza-Flores J. Pharmacokinetics of once-a-month injectable contraceptives. Contraception. 49:1994;347-359.
33. Sang G.-W. Pharmacodynamic effects of once-a-month combined injectable contraceptives. Contraception. 49:1994;361-385.
34. Whigham K.A.E., Howie P.W., Mack A., Prentice C.R.M. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol. 86:1979;806-809.
35. Howard G., Myatt L., Elder M.G. The effects of intramuscular norethisterone enantate used as a contraceptive on IV glucose tolerance and on blood coagulation factors VII and X. Br J Obstet Gynaecol. 84:1977;618-621.
36. Koster T., Rosendaal F.R., Briët E., et al. Protein C deficiency in a controlled series of unselected outpatients an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 85:1995;2756-2761.
37. Koster T., Rosendaal F.R., Reitsma P.H., Van der Velden P.A., Briët E., Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms, Leiden Thrombophilia Study. Thromb Haemost. 71:1994;719-722.
38. Meade T.W., Mellows S., Brozovic M., et al. Haemostatic function and ischaemic heart disease principal results of the Northwick Park Heart Study. Lancet. ii:1986;533-537.
39. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.